Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of 1,2,3,4-Tetrahydroisoquinoline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.52 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.52 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.52 |
| ▸ | PNMT | P11086 | 6/20 | 0.95 |
| ▸ | CD44 | P16070 | 2/20 | 0.95 |
| ▸ | MAOB | P27338 | 1/20 | 0.95 |
| ▸ | HTR2C | P28335 | 1/20 | 0.71 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.52 |
| ▸ | PRCP | P42785 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL5411339 | 1.00 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL5411332 | 1.00 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL29360217 | 0.97 | PNMT (1.00) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL19085 | 0.97 | PNMT (1.00) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL28236302 | 0.97 | PNMT (1.00) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL6635293 | 0.95 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL11213530 | 0.95 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL20524019 | 0.95 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL987515 | 0.95 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL2082936 | 0.95 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051311-B2 | Sulfamide sodium channel inhibitors | AMGEN INC. (US) | 2015-06-09 | — | — | US | disclosed |
| CN-103958018-A | Cationic displacer molecules for hydrophobic displacement chromatography | SACHEM INC | 2014-07-30 | — | — | CN | disclosed |
| WO-2013134518-A1 | SULFAMIDE SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2013-09-12 | — | — | WO | disclosed |
| US-20090036679-A1 | METHOD FOR RESOLVING ENANTIOMERS FROM RACEMIC MIXTURE HAVING CHIRAL CARBON IN ALPHA POSITION OF NITROGEN | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2009-02-05 | — | — | US | disclosed |
| EP-1984358-A1 | METHOD FOR RESOLVING ENANTIOMERS FROM RACEMIC MIXTURE HAVING CHIRAL CARBON IN ALPHA POSITION OF NITROGEN | Chong Kun Dang Pharmaceutical Corp. (KR) | 2008-10-29 | — | — | EP | disclosed |
| WO-2008095852-A1 | BRONCHORELAXING ARYLAMIDES | RESPIRATORIUS AB (SE) | 2008-08-14 | — | — | WO | disclosed |
| WO-2007091753-A1 | METHOD FOR RESOLVING ENANTIOMERS FROM RACEMIC MIXTURE HAVING CHIRAL CARBON IN ALPHA POSITION OF NITROGEN | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2007-08-16 | — | — | WO | disclosed |
| CN-1910149-A | Bronchodilatory compounds | RESPIRATORIUS AB (SE) | 2007-02-07 | — | — | CN | disclosed |
| EP-1507764-A4 | NOVEL ENANTIOMERS OF TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS | YUN-CHOI HYE-SOOK (KR) | 2005-06-22 | — | — | EP | disclosed |
| EP-1507764-A1 | NOVEL ENANTIOMERS OF TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS | Yun-Choi, Hye-Sook (KR) | 2005-02-23 | — | — | EP | disclosed |
| EP-0934276-A1 | ANTHRANILIC ACID DERIVATIVES AS MULTI DRUG RESISTANCE MODULATORS | XENOVA LIMITED (GB) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998017648-A1 | ANTHRANILIC ACID DERIVATIVES AS MULTI DRUG RESISTANCE MODULATORS | XENOVA LIMITED (GB) | 1998-04-30 | — | — | WO | disclosed |
| EP-0707570-A1 | ISOQUINOLINE DERIVATIVES AS THERAPEUTIC AGENTS | Knoll AG (DE) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995000489-A1 | ISOQUINOLINE DERIVATIVES AS THERAPEUTIC AGENTS | KNOLL AG (DE) | 1995-01-05 | — | — | WO | disclosed |
| CN-1096780-A | Therapeutic agents containing novel tetrahydroisoquinoline compounds | BOOTS CO PLC (GB) | 1994-12-28 | — | — | CN | disclosed |
| EP-0618900-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS THERAPEUTIC AGENTS. | BOOTS CO PLC (GB) | 1994-10-12 | — | — | EP | disclosed |
| WO-1993013073-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS THERAPEUTIC AGENTS | THE BOOTS COMPANY PLC (GB) | 1993-07-08 | — | — | WO | disclosed |
| EP-0286293-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PRODUCTION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1992-07-01 | — | — | EP | disclosed |
| CN-1008738-B | The preparation method of cephalosporins derivatives | BANYU PHARMA CO LTD (JP) | 1990-07-11 | — | — | CN | disclosed |
| CN-85109545-A | Process for preparing cephalosporin derivatives | — | 1986-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036679-A1 | METHOD FOR RESOLVING ENANTIOMERS FROM RACEMIC MIXTURE HAVING CHIRAL CARBON IN ALPHA POSITION OF NITROGEN | SRR, NPEPPS, DNPEP | ADRA2A 1963/4885ADRA2B 1969/4885ADRA2C 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.